QNTMHealthcare · BiotechnologyThe 1 Wall Street analysts covering Quantum BioPharma Ltd. hold a median 12-month price target of $12 — +307.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 1 Aug 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Quantum BioPharma Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (88): Smaller than most of the companies we track.
Momentum (8): The shares have been drifting down relative to others.
The rank is the raw material. Whether the rules would actually own Quantum BioPharma Ltd. — and when they’d sell — is the membership.
The bullish and bearish analyst opinions on QNTM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +307.7% from it.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 79% of US stocks
Cheaper than 4% of US stocks
Cheaper than 67% of US stocks
Higher than 35% of US stocks
Higher than 30% of US stocks
Higher than 1% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QNTM appears on the weeks it earns a place.
Quantum BioPharma Ltd. announced the closing of a debt settlement, according to a press release intended for distribution in Canada only.
Why it matters — Closing a debt settlement can improve Quantum BioPharma's balance sheet by resolving outstanding liabilities, which shareholders may view as a step toward financial stability.
The 1 Wall Street analysts covering Quantum BioPharma Ltd. have a median 12-month price target of $12, with estimates ranging from $12 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering Quantum BioPharma Ltd., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Quantum BioPharma Ltd. 39 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 1 Aug 2026, Quantum BioPharma Ltd. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (88 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +307.7% from the last close, and Ticker Nerd's factor model ranks Quantum BioPharma Ltd. 39 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Quantum BioPharma Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QNTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.
Quantum BioPharma Ltd. returned -87.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company focused on researching and developing a portfolio of innovative assets and biotech solutions targeting neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders.
The most recent item we track (GlobeNewsWire, 30 July 2026): "Quantum BioPharma Announces Closing of Debt Settlement". Quantum BioPharma Ltd. announced the closing of a debt settlement, according to a press release intended for distribution in Canada only.
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company focused on researching and developing a portfolio of innovative assets and biotech solutions targeting neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders. Operating through its Biopharmaceutical Innovation and Strategic Investments segments, the company advances drug candidates at various development stages, including its lead compound Lucid-MS, a patented new chemical entity designed to prevent and reverse myelin degradation in multiple sclerosis, currently advancing toward Phase 2 clinical trials. Additional pipeline assets include FSD-PEA for inflammatory diseases like mast cell activation syndrome, Lucid-PSYCH for major depressive disorder, and unbuzzd, a proprietary formulation of vitamins and minerals to support liver and brain function in relieving alcohol consumption effects. Through its subsidiary Lucid Psycheceuticals Inc., Quantum BioPharma drives core R&D efforts, while FSD Strategic Investments Inc. manages a portfolio of secured loans on residential and commercial properties. The company also holds an equity stake and royalties in Unbuzzd Wellness Inc. for the over-the-counter unbuzzd product, alongside a digital asset portfolio as part of its treasury strategy. Headquartered in Toronto, Quantum BioPharma plays a role in addressing unmet needs in central nervous system therapeutics and related health solutions.
CEO Mr. Zeeshan Saeed · 17 employees · Canada · https://www.quantumbiopharma.com